









Markets
/
Stocks
/
nasdaq-mrus
/

Merus NV

MRUS

95.160USD

-0.020-0.02%

Close 11/06, 16:00（ET）Quotes delayed by 15 min

7.22BMarket Cap

LossP/E TTM



Merus NV

95.160

-0.020-0.02%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Merus NV

Currency: USD Updated: 2025-11-06

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Merus NV's Score

Industry at a Glance

Industry Ranking

91 / 407

Overall Ranking

206 / 4615

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 17 analysts

Hold

Current Rating

97.533

Target Price

+2.47%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Merus NV Highlights

StrengthsRisks

Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.

Growing

The company is in a growing phase, with the latest annual income totaling USD 36.13M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 36.13M.

Undervalued

The company’s latest PE is -18.01, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 77.28M shares, decreasing 6.41% quarter-over-quarter.

Held by HACAX

Star Investor HACAX holds 18.98K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-06

The company's current financial score is 6.42, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 12.15M, representing a year-over-year increase of 3.21%, while its net profit experienced a year-over-year increase of 4.39%.

Score

Industry at a Glance

Previous score

6.42

Change



Financials

8.84

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.89

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.57

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.71

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.11

Key Metrics

Free cash flow

No Data

Merus NV's Company Valuation

Currency: USD Updated: 2025-11-06

The company’s current valuation score is 6.76, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -18.01, which is -72.91% below the recent high of -4.88 and -22.11% above the recent low of -21.99.

Score

Industry at a Glance

Previous score

6.76

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 91/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-06

The company’s current earnings forecast score is 6.59, which is lower than the Biotechnology & Medical Research industry's average of 8.00. The average price target for Merus NV is 97.00, with a high of 110.00 and a low of 92.00.

Score

Industry at a Glance

Previous score

6.59

Change

Support & Resistance

No Data

Analyst Rating

Based on 17 analysts

Hold

Current Rating

97.533

Target Price

+2.47%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Merus NV

MRUS

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-06

The company’s current price momentum score is 6.60, which is higher than the Biotechnology & Medical Research industry's average of 6.45. Sideways: Currently, the stock price is trading between the resistance level at 95.56 and the support level at 94.54, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.68

Change

-0.08

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

-1.728

Neutral

RSI(14)

78.678

Buy

STOCH(KDJ)(9,3,3)

74.456

Neutral

ATR(14)

0.354

Low Volatility

CCI(14)

138.607

Buy

Williams %R

19.588

Overbought

TRIX(12,20)

0.452

Sell

StochRSI(14)

80.044

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

95.004

Buy

MA10

94.927

Buy

MA20

94.795

Buy

MA50

83.355

Buy

MA100

72.035

Buy

MA200

58.604

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-06

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.16. The latest institutional shareholding proportion is 101.92%, representing a quarter-over-quarter increase of 2.15%. The largest institutional shareholder is PRFDX, holding a total of 2.26M shares, representing 2.98% of shares outstanding, with 82.82% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

6.22M

+10.56%

Paradigm BioCapital Advisors LP

4.28M

+20.48%

RTW Investments L.P.

4.00M

-4.05%

Wellington Management Company, LLP

3.73M

-21.01%

Commodore Capital LP

3.52M

-21.19%

Deerfield Management Company, L.P.

3.38M

+6.64%

Avoro Capital Advisors LLC

3.16M

+5.19%

T. Rowe Price Associates, Inc.

Star Investors

2.26M

+106.44%

Holocene Advisors, LP

2.23M

+18.77%

Westfield Capital Management Company, L.P.

2.04M

+36.05%

Risk Assessment

Currency: USD Updated: 2025-11-06

The company’s current risk assessment score is 4.79, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 1.06. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.